Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon wish you a merry christmas

Page View:


Christmas is coming up!

Wishing you all the Hope, Wonder, and Joy!

Have a delicious time!

——Warm Regards from Medicilon

Medicilon has made great strides in 2022.

❖ In 2022, about 100 projects that Medicilon participated in gained the approval of clinical trials successfully.

Case: One-Stop R&D Service Platform:From Target To IND


On July 22 2022, CGT-9475, a new generation of ALK inhibitor independently developed by CGeneTech, was approved by the US FDA to enter the clinical trial. Medicilon, which also focuses on innovation, was entrusted by CGeneTech to provide one-stop preclinical comprehensive R&D services for the development of CGT-9475. Under the coordination and collaboration of multiple departments of both parties, Medicilon completed a full set of preclinical research services, providing technical support for CGT-9475 to achieve dual-reporting and dual-approval between China and the United States.

❖Medicilon currently has more than 3,500 scientists and supporting staffs, with 5 R&D centers and a lab space of more than 80,000 square meters.

Medicilon's subsidiary (Hangzhou) Inc. Grandly Opened.The foundation stone laying of Medicilon's subsidiary Medicilon (Baoshan) Inc. was successfully held.

❖We are committed to enhancing our global service and customer experience with our US, Europe, Japan, and Korea offices!

❖We have won a number of heavyweight awards such as "Top 30 Listed Companies on the Sci-Tech Innovation Board", "Top 20 Most Influential CXO Enterprises", “2022 Shanghai Top 100 Growth Enterprises”, etc.

❖We have established some new service platforms such as:

>>    ADC R&D Service Platform;

>>    Nucleic Acid Drug R&D Platform;

>>    CMC&CDMO Service Platform;

>>    Flow Cytometry Technology Platform;

>>    Preclinical Efficacy Evaluation Service Platform for Cerebrovascular Disease, et al.

We are also preparing a great 2023 year …

But for now, we wish you great Christmas holidays, full of joy and peaceful !

We present a “Chemistree” specially for you.

Step by step we are getting closer to 2023, after a very particular and, for some of us, very difficult 2022 year. We will be happy to facilitate your pathway on this road with our professional pharmaceutical preclinical integrated R&D service and our know-how. Many thanks to all our partners and collaborators around the world!

Look forward to a promising future together.


Contact Us-



❖ 585 Chuanda Rd, Pudong, Shanghai, China, 201299 (Headquarters)

❖ 1 Broadway, 9th Fl, Cambridge Innovation Center, Cambridge, MA 02142, US

❖ Kelvinstraat 41b, 6601 HH Wijchen, The Netherlands

❖ Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Relevant newsRelevant news